Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• Patients infected by HIV-1 and HBV or HCV

• Age ≥18 years

• Patients who were initiated on a LPV/r containing antiretroviral (ARV) regimen

Exclusion Criteria:

• Contraindications as described in SmPC (summary of product characteristics) at the time of prescription